Medtronic’s FY26 Q4: A Steady Pulse, New Growth Signals, and a Dividend Beat

Overview and SEO-friendly context

Medtronic plc (MDT) reported its fourth-quarter and full-year results for fiscal year 2026, delivering an EPS mix of GAAP 0.96 and non-GAAP 1.55 on revenue of $9.8 billion in Q4. The quarter logged a 9.9% increase on a reported basis and 6.6% organic growth, coming in about 90 basis points ahead of Q4 implied guidance. For the full year, Medtronic announced revenue of about $36.4 billion and non-GAAP EPS of $5.53, with GAAP EPS of $3.73. This release treads a clear line between disciplined execution and an explicit push into growth adjacencies, a narrative that matters for EPS consensus trajectories and the revenue forecast many investors watch as 2027 begins to approach.

Q4 Key Highlights

Revenue of $9.8 billion, up 9.9% as reported and 6.6% organic; about 90 bps ahead of Q4 implied guidance.
GAAP EPS of $0.96; non-GAAP EPS of $1.55, both ahead of guidance.
Cardiac Ablation Solutions revenue rose ~78% globally, with ~124% U.S. growth, lifting U.S. share in a meaningful way.
Cardiovascular overall grew ~10.1%, led by mid-single-digit growth in Cardiac Rhythm Management.
Defibrillation Solutions highlighted mid-teens growth in Micra and a strong OmniaSecure U.S. launch.
Medical Surgical segment posted solid performance; notable FDA activity and product clearances in the pipeline.
Dividend for Q1 FY27 increased to $0.72 per share, implying an annual payout of about $2.88 per share; continued dividend growth for the 49th consecutive year.

FY26 Highlights and what they signal

On a full-year basis, Medtronic reported revenue of $36.4 billion and an adjusted revenue figure of $36.3 billion, with GAAP EPS of $3.73 and non-GAAP EPS of $5.53. The company noted that FY26 operating margin was flat year over year, while the non-GAAP operating margin declined by about 130 basis points (roughly 150 bps on a constant-currency basis).

The results underscore a portfolio of high-growth components within Cardiac and Defibrillation Solutions, alongside ongoing strategic tuck-ins and partnerships. The company also highlighted progress in regulatory and market validation across multiple devices, which matters for long-run EPS growth and margin trajectory as it scales new franchises.

Strategic momentum: products, approvals, and acquisitions

Medtronic emphasized strength in Cardiac Ablation and Defibrillation as primary growth engines, with Micra and OmniaSecure features driving mid-to-high-teens growth within the Defibrillation Solutions line. In Medical Surgical, the company pointed to robust performance in Acute Care & Monitoring and Endoscopy, supported by a slate of regulatory clearances and submissions.

The company also carried forward a vigorous M&A and collaboration program. Notable items include a completed CathWorks acquisition to strengthen coronary and renal denervation capabilities, and announced intentions to acquire Scientia Vascular in Neurovascular and SPR Therapeutics in Neuromodulation (announced in May). In addition, Medtronic noted tuck-in discussions with Merit Medical Systems to offer ViaVerte for Neuromodulation, alongside an investment in Pulnovo Medical in Cardiovascular.

Regulatory and product milestones

The firm reported FDA clearances for Spine, Cranial, and ENT indications and a CE Mark for Spine and Cranial indications for the Stealth AXiS Surgical System. Submissions and clearances across Hugo RAS for general surgery and gynecologic indications, as well as LigaSure RAS vessel sealer, were highlighted, with ProGrip Advanced receiving FDA clearance. These milestones are the sort of regulatory tailwinds that can influence the revenue forecast and the underlying growth narrative.

Capital returns and investor signals

The dividend increase to $0.72 per share for Q1 FY27, paired with a stated annual payout of about $2.88 per share and the long run of dividend growth (the 49th consecutive year), underscores Medtronic’s prioritization of cash return alongside growth investments. That combination can be appealing to equity investors who weigh EPS trajectory and revenue forecast alongside dividend discipline.

Outlook for peers and the sector

The quarter’s strength across Cardiac and Defibrillation Solutions suggests ongoing demand for advanced rhythm-management devices and next-generation implantable therapies. For sector peers, the Medtronic playbook—strong product cycles, selective M&A, regulatory acceleration, and a commitment to returns—is a blueprint that may shape near-term competitive dynamics. If the company sustains margin discipline while expanding in high-growth devices, the earnings narrative could shift toward a steadier EPS consensus uplift rather than the quick headline moves seen in more volatile cycles. Investors will want to watch how SIM devices, regulatory timelines, and international growth pockets contribute to the revenue forecast into fiscal 2027 and beyond.

Bottom line: a measured rhythm with growth chords

Medtronic’s FY26 Q4 results read like a well-composed balance of durable cardiac franchises and a disciplined capital-allocation plan. The company executes in key growth areas, advances a robust regulatory and product pipeline, and returns capital to shareholders while signaling a steady path toward a higher EPS trajectory. For the sector, the message is more about breadth than a single hero product—an ecosystem strategy that could influence earnings surprise timing and the EPS consensus over the next few quarters.